SUBSCRIBE
SUBSCRIBE
News   Policy

Pro-Pharmaceuticals, Inc. Races to Get Lead Product OK’d

September 29, 2008 | 
1 min read

Pro-Pharmaceuticals Inc. is the latest struggling biotech company to face a major cash crunch, even as it comes close to submitting its lead compound to treat cancer for FDA approval.

Regulatory
MORE ON THIS TOPIC
Pictured: Sign of U.S. Department of Health & Huma
IRA
CMS Releases Updated Medicare Drug Price Negotiation Guidance, Offers More Flexible Timeline
October 3, 2024
 · 
1 min read
 · 
Tristan Manalac
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
October 2, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: A scientist works behind an FDA sign/Tay
FDA Tracker
J&J’s Stelara Gets New Biosimilar Competition From Fresenius Kabi and Formycon
October 1, 2024
 · 
187 min read
 · 
Heather McKenzie
Pictured: Bristol Myers Squibb office in California
Legal
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition
October 1, 2024
 · 
1 min read
 · 
Tristan Manalac